ReviewThrombosis research2012
Platelet tissue factor pathway inhibitor modulates intravascular coagulation.
Review in Thrombosis research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Platelet homeostasis and heterogeneity in inflammation and sepsis: mechanisms, biological effects, and clinical potential.Cell communication and signaling : CCS · 2026Review
- Targeting cargo to an unconventional secretory system within megakaryocytes allows the release of transgenic proteins from platelets.Journal of thrombosis and haemostasis : JTH · 2024Article
- Exploring the Hemostatic Effects of Platelet Lysate-Derived Vesicles: Insights from Mouse Models.International journal of molecular sciences · 2024Article
- Thrombin generation abnormalities in commonly encountered platelet function disorders.International journal of laboratory hematology · 2021Article
- Endothelial cell dysfunction, coagulation, and angiogenesis in coronavirus disease 2019 (COVID-19).Microvascular research · 2021Review
- Factors Associated with Low Admission Platelet Count in Adults with Acute Aortic Dissection.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2019Article
- Quantitative high-throughput profiling of snake venom gland transcriptomes and proteomes (Ovophis okinavensis and Protobothrops flavoviridis).BMC genomics · 2013Article
- Regulation of factor V and factor V-short by TFPIα: Relationship between B-domain proteolysis and binding.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Tissue factor pathway inhibitor (TFPI) is produced by megakaryocytes and is found internally within quiescent platelets but is not in α-granules. It is released in soluble form and expressed on the surface of platelets that are dual activated with thrombin plus collagen. Platelet TFPI is exclusively TFPIα, the most evolutionarily conserved TFPI isoform. It appears to be physiologically active as an inhibitor of tissue factor (TF) initiated FXa generation in vitro, and acts locally to dampen clot growth in a murine vascular injury model. These data suggest that platelet TFPI plays an important role in modulating TF activity within a growing clot thereby preventing formation of an occlusive clot.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.